108 BioCapital backs Pinwheel Therapeutics with $20 million for ciraparantag development
VCCircle · February 5, 2026 · Financing announcement
NEWS & PUBLICATIONS
Follow the evidence.
Investigational product
Selected milestones and peer-reviewed research in ciraparantag’s development.
NEWS
Selected Milestones
EMA agrees to a paediatric investigation plan for ciraparantag
European Medicines Agency decision P/0421/2023
Apixaban and rivaroxaban Phase 2 findings published online
European Heart Journal
AMAG completes acquisition of Perosphere Pharmaceuticals
Transaction added global ciraparantag rights to AMAG’s development portfolio
AMAG announces agreement to acquire Perosphere Pharmaceuticals
Announcement describes ciraparantag’s clinical-stage program and FDA Fast Track designation
PUBLICATIONS
Peer-Reviewed Research
Publication titles reflect the authors’ original wording. Historical study findings should be interpreted in the context of the full body of evidence and do not establish clinical hemostatic efficacy in patients with major bleeding.
Reversal of Direct Oral Anticoagulants: Meeting a Need & Filling a Gap
Medical Research Archives 11(7.1) · Review of direct oral anticoagulant reversal strategies and ciraparantag
A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents
Drug Discovery Today 27(10):103332 · Review of preclinical and clinical evidence
Ciraparantag as a potential universal anticoagulant reversal agent
European Heart Journal 43(10):993–995 · Editorial commentary on the apixaban and rivaroxaban Phase 2 studies
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
European Heart Journal 43(10):985–992 · Phase 2 studies NCT03288454 and NCT03172910
Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants
Blood 137(1):115–125 · Original research on mechanism of action, pharmacokinetics, and reversal in animal bleeding models
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
Thrombosis and Haemostasis 117(2):238–245 · Clinical trial NCT01826266
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin
Thrombosis Research 146:113–118 · Phase 1/2 healthy-volunteer study
Use of PER977 to reverse the anticoagulant effect of edoxaban
The New England Journal of Medicine 371:2141–2142 · Early human pharmacodynamic findings